GeoVax To Present at Upcoming Immuno-Oncology Conference

GeoVax Labs (OTCQB:GOVX) announced their chief scientific officer, Dr. Farshad Guirakhoo will give two talks during the Immuno-Oncology Summit on the company’s vaccine programs.

As quoted in the press release:

Dr. Guirakhoo’s presentations will be delivered during the Advances in Vaccine Technologies session on August 30.

Dr. Guirakhoo’s first presentation, entitled “A Novel Alternative Approach to Develop a Safe Vaccine for Zika,” will discuss GeoVax’s development of a safe and effective vaccine against Zika virus (ZIKV), an urgent global health priority. The Company’s vaccine candidate, GEO-ZM02, demonstrated 100% protection against lethal challenge after a single dose in a rigorous mouse model. Unlike other vaccines currently in development, which rely on ZIKV structural proteins, GEO-ZM02 is based on the NS1 antigen that does not carry the risk of Antibody Dependent Enhancement (ADE) of infection and could potentially block transmission of ZIKV from humans back to its mosquito host.

Click here to read the full press release.

Get the Latest Biotech Investing Stock Information

Get the latest information about companies associated with Biotech Investing delivered directly to your inbox.


By selecting company or companies above, you are giving consent to receive email from those companies. And remember you can unsubscribe at any time.

Biotech Stocks in 2018

Find out how the market will look this year


Leave a Reply